Clinical Trial Update: Pharmacogenetic and Pharmacokinetics of Naproxen and Associated Naproxen-esomeprazole [Phase 4]

View source ↗

Summary

A Phase 4 pharmacogenetic and pharmacokinetic study assessing naproxen and naproxen-esomeprazole in individuals with CYP2C9 and CYP2C19 poor metabolizer variant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Disorders
• Pain

Drugs mentioned

• Naproxen (Naproxen)
• naproxen-esomeprazole (naproxen-esomeprazole)

Snippet

Sponsor: University of Sao Paulo | Conditions: Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome p450 CYP2C19 Variant | Phase 4 | Status: COMPLETED